Drug Type Oncolytic virus |
Synonyms CG 0070, CG-0070, CG0700 |
Target |
Action stimulants |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Breakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | United States | 27 Oct 2020 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Japan | 27 Oct 2020 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Australia | 27 Oct 2020 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Taiwan Province | 27 Oct 2020 | |
Papillary carcinoma in situ | Phase 3 | United States | 01 Mar 2014 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 3 | United States | 01 Mar 2014 | |
Carcinoma of urinary bladder, invasive | Phase 2 | United States | 01 Mar 2014 | |
Muscle Invasive Bladder Carcinoma | Phase 1 | United States | 26 Oct 2020 | |
Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | United States | 01 Apr 2005 | |
Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Canada | 01 Apr 2005 |
Phase 3 | 110 | wtsecxjwsd(vpdwsinzgm) = ywjfhzmkna kbzxdknmsu (kqmmblxfrh, 52.4 - 73.7) View more | Positive | 01 May 2025 | |||
Phase 3 | 110 | ngvguhuvnq(nsbeuwzlak) = piudsatvdk ekiqerdktf (bqygrwunxx, 66.3 - 83.2) View more | Positive | 24 Mar 2025 | |||
Phase 3 | 112 | rbtmyhvebb(ixkmkizoes) = vicuwnqmms tftvglpsky (eolxvnsgxr, 65.4 - 82.4) View more | Positive | 05 Dec 2024 | |||
Phase 2 | Non-Muscle Invasive Bladder Neoplasms alterations in the retinoblastoma pathway | GM-CSF transgene | viral receptor expression ... View more | 35 | wrhepgfxrz(ovrjkbbmeb) = qfnavuukyv lfdfnbstbu (ebqseafbun, 40 - 73) View more | Positive | 24 May 2024 | ||
Phase 3 | 112 | Cretostimogene monotherapy | haoqnhvbfg(bwswtrdfjb) = tjzggzrrhx kejiydfcnf (fuzqzdhqmr, 65 - 83) View more | Positive | 03 May 2024 | ||
Phase 3 | 66 | cretostimogene grenadenorepvec | artbbadnan(hcdafqlvdg) = idyfsxcfzr qrdxrgqvwp (rbrszagwiy, 63 - 85) View more | Positive | 07 Dec 2023 | ||
Phase 1 | Non-Muscle Invasive Bladder Neoplasms Neoadjuvant | 21 | fudzkhdvte(jvtkhxbsrr) = lqkugeewlm kxvqtjlohw (vcgwfitbti ) View more | Positive | 31 May 2023 | ||
Phase 2 | Non-Muscle Invasive Bladder Neoplasms mutated or deficient RB | 35 | rritlgvyhc(ajyghzfzym) = ffsvdisdkk fviphcnfoe (dajbrossma ) View more | - | 01 Apr 2023 | ||
deuirmvcze(zvuaoedcgu) = cgkdjrrtdn oyingdzxwt (pjjzffggqv ) View more | |||||||
Phase 2 | 32 | hjfoxyawvu(jwsitbdgsc) = hcosiyqlhk xarsomsxnx (hwpmndpccz ) View more | Positive | 10 Nov 2022 | |||
Phase 3 | 110 | nxamnubrob(frewozcwwv) = ywawchthzk vftkgfxrhh (pvrjbvpwfb ) | - | 15 Jun 2022 |